TY - JOUR
T1 - Vascular risk factors and cognitive impairment in a stroke-free cohort
AU - Unverzagt, F. W.
AU - McClure, L. A.
AU - Wadley, V. G.
AU - Jenny, N. S.
AU - Go, R. C.
AU - Cushman, M.
AU - Kissela, B. M.
AU - Kelley, B. J.
AU - Kennedy, R.
AU - Moy, C. S.
AU - Howard, V.
AU - Howard, G.
N1 - Funding Information:
Dr. Unverzagt has served as a consultant to Eli Lilly and Company; serves on the editorial boards of the Journal of the International Neuropsychological Association and Neuropsychology ; receives research support from the NIH and Posit Science Inc; and holds stock in Eli Lilly and Company. Dr. McClure serves on a Data Monitoring Committee for the NIH/NINDS and receives research support from Genzyme Corporation, the NIH (NINDS, NICHD, NHLBI), and NASA. Dr. Wadley has received funding for travel from Amgen; serves on the editorial board of Current Gerontology and Geriatrics Research ; and receives research support from Genzyme Corporation, the NIH, and the Jefferson County Office of Senior Citizens Services. Dr. Jenny serves on the editorial board of Arteriosclerosis, Thrombosis and Vascular Biology ; serves as a consultant for Tethys Bioscience, Inc.; receives research support from GlaxoSmithKline, the NIH, and the American Diabetic Association; and holds stock in Haematologic Technologies, Inc. Dr. Go receives research support from the NIH/NINDS. Dr. Cushman serves on the editorial boards of the Journal of Thrombosis and Haemostasis , Circulation , Archives of Internal Medicine , and the Journal of Thrombosis and Thrombolysis ; and receives/has received research support from Amgen, GlaxoSmithKline, and the NIH. Dr. Kissela serves on scientific advisory boards for Northstar Neuroscience and Allergan, Inc.; has received funding for travel and speaker honoraria from Allergan, Inc.; has received research support from NexStim and the NIH; and provides medico-legal reviews. Dr. Kelley receives/has received research support from Novartis and the NIH. Dr. Kennedy receives research support from the NIH (NINDS, NIA, NIDDK). Dr. Moy reports no disclosures. Dr. V. Howard serves/has served on scientific advisory boards for Amgen, Boehringer-Ingelheim, Mitsubishi, PhotoThera, and MediciNova; her spouse serves on a scientific advisory boards for Bayer Schering Pharma; has received funding for travel from Amgen; serves as a consultant for NIH review committees; her spouse has provided legal consulting for Merck Serono; and receives research support from the NIH (NINDS, NIDDK, NIOSH). Dr. G. Howard serves/has served on scientific advisory boards for Bayer Schering Pharma, Abbott, Boehringer Ingelheim, BrainsGate, Cerevast Therapeutics, Inc., CoAxia, Inc., MediciNova, Inc., Mitsubishi Tanabe Pharma Corporation, and PhotoThera; serves as Stroke Section Editor for the Journal of The American Society of Hypertension ; and receives research support from Amgen and the NIH (NINDS, NIAMS, NICHD, NHLBI).
PY - 2011/11/8
Y1 - 2011/11/8
N2 - Objective: To examine vascular risk factors, as measured by the Framingham Stroke Risk Profile (FSRP), to predict incident cognitive impairment in a large, national sample of black and white adults age 45 years and older. Methods: Participants included subjects without stroke at baseline from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study with at least 2 cognitive function assessments during the follow-up (n=23,752). Incident cognitive impairment was defined as decline from a baseline score of 5 or 6 (of possible 6 points) to the most recent follow-up score of 4 or less on the Six-item Screener (SIS). Subjects with suspected stroke during follow-up were censored. Results: During a mean follow-up of 4.1 years, 1,907 participants met criteria for incident cognitive impairment. Baseline FSRP score was associated with incident cognitive impairment. An adjusted model revealed that male sex (odds ratio [OR]=1.59, 95% confidence interval [CI] 1.43-1.77), black race (OR=2.09, 95% CI 1.88-2.35), less education (less than high school graduate vs college graduate, OR=2.21, 95% CI 1.88-2.60), older age (10-year increments, OR=2.11, per 10-year increase in age, 95% CI 2.05-2.18), and presence of left ventricular hypertrophy (LVH, OR=1.29, 95% CI 1.06-1.58) were related to development of cognitive impairment. When LVH was excluded from the model, elevated systolic blood pressure was related to incident cognitive impairment. Conclusions: Total FSRP score, elevated blood pressure, and LVH predict development of clinically significant cognitive dysfunction. Prevention and treatment of high blood pressure may be effective in preserving cognitive health.
AB - Objective: To examine vascular risk factors, as measured by the Framingham Stroke Risk Profile (FSRP), to predict incident cognitive impairment in a large, national sample of black and white adults age 45 years and older. Methods: Participants included subjects without stroke at baseline from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study with at least 2 cognitive function assessments during the follow-up (n=23,752). Incident cognitive impairment was defined as decline from a baseline score of 5 or 6 (of possible 6 points) to the most recent follow-up score of 4 or less on the Six-item Screener (SIS). Subjects with suspected stroke during follow-up were censored. Results: During a mean follow-up of 4.1 years, 1,907 participants met criteria for incident cognitive impairment. Baseline FSRP score was associated with incident cognitive impairment. An adjusted model revealed that male sex (odds ratio [OR]=1.59, 95% confidence interval [CI] 1.43-1.77), black race (OR=2.09, 95% CI 1.88-2.35), less education (less than high school graduate vs college graduate, OR=2.21, 95% CI 1.88-2.60), older age (10-year increments, OR=2.11, per 10-year increase in age, 95% CI 2.05-2.18), and presence of left ventricular hypertrophy (LVH, OR=1.29, 95% CI 1.06-1.58) were related to development of cognitive impairment. When LVH was excluded from the model, elevated systolic blood pressure was related to incident cognitive impairment. Conclusions: Total FSRP score, elevated blood pressure, and LVH predict development of clinically significant cognitive dysfunction. Prevention and treatment of high blood pressure may be effective in preserving cognitive health.
UR - http://www.scopus.com/inward/record.url?scp=82955210332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955210332&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318236ef23
DO - 10.1212/WNL.0b013e318236ef23
M3 - Article
C2 - 22067959
AN - SCOPUS:82955210332
SN - 0028-3878
VL - 77
SP - 1729
EP - 1736
JO - Neurology
JF - Neurology
IS - 19
ER -